A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH: APD811-301

  • Brown, Martin (Primary Chief Investigator)
  • Butala, Radhika, (Clinical Trial Unit Staff)
  • Chapman, Nicola, (Clinical Trial Unit Staff)

Project: Research

Short titleARENA 301
AcronymADVANCE-outcomes
StatusActive
Effective start/end date17/10/1930/06/22